Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENC-101-hPTG is an investigational encapsulated cell therapy being developed by Encellin for the treatment of severe refractory hypoparathyroidism. The therapy utilizes Encellin's proprietary Encapsulated Cell Replacement Therapy (ENCRT) platform, which consists of a nanoporous, immunoprotective, and pro-angiogenic membrane pouch. This pouch is loaded with primary human parathyroid gland (PTG) cells. Once implanted subcutaneously, the device is designed to protect the allogeneic parathyroid cells from host immune rejection and fibrosis while allowing the free exchange of nutrients, calcium, and parathyroid hormone (PTH). By restoring physiological PTH secretion, ENC-101-hPTG aims to regulate systemic calcium homeostasis without requiring lifelong immunosuppression or daily hormone injections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ENC-101-hPTG.